Fundraising FoxInterius BioTherapeutics
Philadelphia, US · Founded 2019 · 10 known investors
Find your way into Interius BioTherapeutics
Sign up to see every warm intro you have to Interius BioTherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Interius BioTherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Interius BioTherapeutics was founded in 2019 by Philip R. Johnson, M.D..
Board
Investors · 10
How we know: Agent Capital's portfolio page · a partner's Signal profile · press coverage · the VCSheet dataset · Not right? Tell us
How we know: DC Investment Partners's portfolio page · Not right? Tell us
How we know: Longwood Fund's portfolio page · press coverage · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: a partner's Signal profile · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$118.1M disclosed across 4 rounds · 2020–2024
▶$51.4MraisedJun 2024 · 12 investors · BiotechnologyRule 506(b)
- Leon O. MoulderDirector
- Tomas KiselakDirector
- Bihua ChenDirector
- Leon Moulder, Jr.Director
- Dora MitchellExecutive Officer
- Philip R. Johnson, M.D.Executive Officer, Director
- Offering amount
- $82.5M
- Amount sold
- $51.4M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$21.5MraisedOct 2023 · 13 investors · BiotechnologyRule 506(b)
- Tomas KiselakDirector
- Benjamin LundDirector
- Leon Moulder, Jr.Director
- Philip R. JohnsonExecutive Officer, Director
- Dora MitchellExecutive Officer
- Offering amount
- $21.5M
- Amount sold
- $21.5M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$43.6MraisedMay 2021 · 25 investors · BiotechnologyRule 506(b)
- Dora MitchellExecutive Officer
- Tomas KiselakDirector
- Lori ForrestExecutive Officer
- Leon Moulder, Jr.Director
- Benjamin LundDirector
- Philip R. Johnson, M.D.Executive Officer, Director
- Offering amount
- $76.3M
- Amount sold
- $43.6M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.6MraisedMar 2020 · 5 investors · BiotechnologyRule 506(b)
- Saar GillExecutive Officer
- Bruce PeacockExecutive Officer, Director
- Leon O. Moulder, Jr.Director
- Offering amount
- $3.1M
- Amount sold
- $1.6M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who founded Interius BioTherapeutics?
- Interius BioTherapeutics was founded by Philip R. Johnson, M.D. in 2019.
- Who are Interius BioTherapeutics's investors?
- Interius BioTherapeutics's investors include Agent Capital, DC Investment Partners, Longwood Fund, OUP (Osage University Partners), Pfizer Venture Investments, Quan Capital, Bain Capital Life Sciences, BrightEdge and 2 more.
- How much funding has Interius BioTherapeutics raised?
- Interius BioTherapeutics has disclosed $118.1M raised across 4 rounds.
- Where is Interius BioTherapeutics headquartered?
- Interius BioTherapeutics is headquartered in Philadelphia, US.